<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01898884</url>
  </required_header>
  <id_info>
    <org_study_id>20629-100</org_study_id>
    <nct_id>NCT01898884</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Multicenter, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral VP 20629 in Adult Subjects With Friedreich's Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study are:

        -  To evaluate the safety and tolerability of single and multiple oral doses of VP 20629 in
           subjects with Friedreich's ataxia (FA). [Primary]

        -  To characterize the pharmacokinetics of VP 20629 by investigation of the plasma
           concentration-time profile following single and multiple oral doses in subjects with FA.
           [Secondary]

        -  To investigate the pharmacodynamic effects of VP 20629 on plasma 8-isoprostane and
           malondialdehyde and urinary 8-hydroxydeoxyguanosine concentrations following multiple
           oral doses in subjects with FA. [Exploratory]
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>From Start of Study Treatment up to Day 19</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs (TEAEs), defined as all AEs that start during study drug treatment (and up to 7 days after the last dose of the study drug) and were not seen at baseline, or were seen at baseline but increased in frequency and/or severity during study drug treatment (and up to 7 days after the last dose of study drug).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Laboratory Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From Start of Study Treatment up to Day 19</time_frame>
    <description>An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Treatment-emergent were events between first dose of study drug and 7 days after the last dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with Grade 3 or higher treatment-emergent adverse events for laboratory abnormalities were reported as clinically relevant laboratory changes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From Start of Study Treatment up to Day 19</time_frame>
    <description>Vital sign assessments included systolic blood pressure, diastolic blood pressure, heart rate, and temperature. Vital signs abnormalities reported as TEAEs were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Relevant Electrocardiogram (ECG) Abnormalities Recorded as Adverse Events (AEs)</measure>
    <time_frame>From Start of Study Treatment up to Day 19</time_frame>
    <description>ECG included PR interval, QRS interval, QTcB interval, QTcF interval were considered as clinically significant ECG abnormalities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
    <description>The Cmax is the maximum observed plasma concentration of single dose of VP 20629 and VP 20631.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Observed Plasma Concentration (Tmax) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
    <description>The Tmax is the time to reach maximum observed plasma concentration of single dose of VP 20629 and VP 20631.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
    <description>The AUC is the area under the plasma concentration-time curve observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC[0-8]) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, and 8 hours Postdose on Day 1</time_frame>
    <description>The AUC(0-8) is the area under the plasma concentration-time curve from time zero to 8 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve to the Last Measurable Plasma Concentration (AUCt) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
    <description>The AUCt is the measure of the plasma drug concentration from time zero to time t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Plasma Half-Life (t1/2) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
    <description>The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vz/F) of VP 20629 for Single Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
    <description>The Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Drug Clearance (CL/F) of VP 20629 for Single Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate Constant (Lambda[z]) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
    <description>Lambda(z) is first-order elimination rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amount Excreted Into the Urine (Ae) for Unchanged VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</measure>
    <time_frame>0-4, 4-8, 8-16, 16-24, 24-36 and 36-48 hours postdose on Day 1</time_frame>
    <description>The Ae is the amount of drug excreted in urine. It is calculated by multiplying the urinary volume with the urinary drug concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Drug Excreted in Urine (Ae%) of VP 20629 for Single Dose Groups</measure>
    <time_frame>-4, 4-8, 8-16, 16-24, 24-36 and 36-48 hours postdose on Day 1</time_frame>
    <description>The Ae% is the percentage of drug dose excreted into the urine calculated as (Ae divided by dose)∗100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CLR) of VP 20629 for Single Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
    <description>The CLR is the renal clearance of the drug, calculated as Ae/AUC(0-infinity) on Day 1 or Ae(0-24)/AUC(0-24) on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 24 and 72 hours Postdose on Day 1</time_frame>
    <description>The Cmax is the maximum observed plasma concentration of Multiple Dose of VP 20629 and VP 20631.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration at Steady State (Cmax,ss) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
    <description>The Cmax,ss is the maximum observed plasma concentration at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Observed Plasma Concentration (Tmax) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 24 and 72 hours Postdose on Day 1</time_frame>
    <description>The Tmax is the time to reach maximum observed plasma concentration of multiple dose of VP 20629 and VP 20631.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Observed Plasma Concentration at Steady State (Tmax,ss) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
    <description>The Tmax,ss is the time to reach maximum observed plasma concentration at steady state of multiple dose of VP 20629 and VP 20631.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
    <description>The AUC is the area under the plasma concentration-time curve observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve at Steady State (AUCss) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, and 8 hours Postdose on Day 8</time_frame>
    <description>The AUCss is the area under the plasma concentration time curve observed during a dosing at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC[0-8]) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6 and 8 hours Postdose on Day 1</time_frame>
    <description>The AUC(0-8) is the area under the plasma concentration-time curve from time zero to 8 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUCt) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
    <description>The AUCtau is the measure of the plasma drug concentration from time zero to time t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Plasma Half-Life (t1/2) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
    <description>The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vz/F) of VP 20629 for Multiple Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
    <description>The Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Drug Clearance at Steady State (CLss/F) of VP 20629 for Multiple Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate Constant (Lambda[z]) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
    <description>Lambda(z) is first-order elimination rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amount Excreted Into the Urine at Steady State (Ae,ss) of Unchanged VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</measure>
    <time_frame>0-4, 4-8, 8-16, 16-24, 24-36, and 36-48 hours postdose on Day 8</time_frame>
    <description>The Ae,ss is the amount of drug excreted in urine. It is calculated by multiplying the urinary volume with the urinary drug concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Drug Excreted in Urine at Steady-State (Ae%,ss) of VP 20629 for Multiple Dose Groups</measure>
    <time_frame>0-4, 4-8, 8-16, 16-24, 24-36, and 36-48 hours postdose on Day 8</time_frame>
    <description>The Ae%,ss is the percentage of drug dose excreted into the urine calculated as (Ae divided by dose)∗100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance at Steady State (CLR,ss) of VP 20629 for Multiple Dose Groups</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
    <description>The CLR,ss is the renal clearance of the drug, calculated as Ae/AUC(0-infinity) on Day 8.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Friedreich's Ataxia</condition>
  <arm_group>
    <arm_group_label>Single dose of VP 20629 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four groups of 8 subjects each will receive a single dose of VP 20629 (150 mg, 450 mg, 900 mg, or 1200 mg) or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple doses of VP 20629 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three groups of 8 subjects each will receive multiple doses of VP 20629 (300 mg, 600 mg, or 900 mg total daily dose) or placebo. VP 20629 or placebo will be administered every 8 hours for 7 days with a single morning dose on Day 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP 20629</intervention_name>
    <arm_group_label>Single dose of VP 20629 or placebo</arm_group_label>
    <arm_group_label>Multiple doses of VP 20629 or placebo</arm_group_label>
    <other_name>Indole-3-propionic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Single dose of VP 20629 or placebo</arm_group_label>
    <arm_group_label>Multiple doses of VP 20629 or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be 18 to 45 years of age (inclusive).

          2. Have a body mass index between 18 and 27 kg/m^2 (inclusive).

          3. Have a clinical presentation consistent with FA.

          4. Have a confirmed diagnosis of FA with a defined expanded guanosine, adenine, adenine
             (GAA) triplet repeat number.

          5. Have an International Cooperative Ataxia Rating Scale (ICARS) mean total score of ≤75.

          6. If female, be postmenopausal (cessation of menses ≥1 year), surgically sterile, or
             have a negative serum human chorionic gonadotropin pregnancy test within 5 days prior
             to the first dose of study drug. Women of child bearing potential must also be on an
             acceptable method of birth control, as determined by the Investigator, for 3 months
             prior to the first dose and must agree to continue use through 2 months after the last
             dose of study drug.

             If male, be surgically sterile or agree to follow an acceptable method of birth
             control as determined by the Investigator, from the screening visit through 2 months
             after the last dose of study drug.

          7. Be able to swallow capsules whole.

          8. Agree to adhere to the protocol-defined schedule of assessments and procedures.

          9. Be informed of the nature of the study and provide written informed consent before any
             study-specific procedures are performed.

        Exclusion Criteria:

          1. Have taken coenzyme Q10, idebenone, other dietary or herbal supplements (with an
             anti-oxidative effect), or over-the-counter medications (including homeopathic
             medicines and vitamins) within 1 week prior to the first dose of study drug on Day 1.

          2. If female, be pregnant or breastfeeding.

          3. Have a positive test result for human immunodeficiency virus (HIV), hepatitis B
             surface antigen, or hepatitis C antibody.

          4. Have ingested any alcohol within 48 hours before admission to the clinical study unit
             on Day -1. NOTE: Caffeine intake should be limited to 2 caffeine-containing beverages
             per day during this same time period.

          5. Have participated in an investigational drug trial within 30 days prior to the first
             dose of study drug on Day 1. NOTE: Subjects who received study drug (VP 20629 or
             placebo) in a single-dose group in this study and completed the Post-treatment Safety
             Assessment are allowed to enroll in a multiple-dose group following a 21 day washout
             period, provided they continue to meet protocol eligibility criteria. Subjects cannot
             enroll in a multiple-dose group if they have an ongoing adverse event following
             participation in a single-dose group or had a serious adverse event during a
             single-dose group (regardless of causality).

          6. Have a known hypersensitivity to any ingredient in the study formulation.

          7. Have, as determined by the Investigator and/or medical monitor, any clinically
             relevant medical or surgical condition that could interfere with the administration of
             study drug, interpretation of study results, or compromise the safety or well-being of
             the subject.

          8. Have a Columbia-Suicide Severity Rating Scale (C-SSRS) score of 4 or 5.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gwendolyn Niebler, DO</last_name>
    <role>Study Director</role>
    <affiliation>ViroPharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2013</study_first_posted>
  <results_first_submitted>June 16, 2016</results_first_submitted>
  <results_first_submitted_qc>August 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 6, 2016</results_first_posted>
  <last_update_submitted>August 12, 2016</last_update_submitted>
  <last_update_submitted_qc>August 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This is a multicenter study conducted between 13 August 2013 and 18 June 2015.</recruitment_details>
      <pre_assignment_details>A total of 46 participants were enrolled to the study, of which 32 were randomly assigned to single-dose group and 24 were randomly assigned to multiple-dose group. Participants who received investigational product in a single-dose group and completed the post-treatment safety assessment were allowed to enrol in a multiple-dose group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Dose Placebo</title>
          <description>Participants received placebo matching to single dose of VP 20629 capsules orally under fasting condition on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Single Dose VP 20629 150 mg</title>
          <description>Participants received single dose of VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Single Dose VP 20629 450 mg</title>
          <description>Participants received single dose of VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Single Dose VP 20629 900 mg</title>
          <description>Participants received single dose of VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Single Dose VP 20629 1200 mg</title>
          <description>Participants received single dose of VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Multiple Dose Placebo</title>
          <description>Participants received placebo matching to multiple doses of VP 20629 capsules orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
        </group>
        <group group_id="P7">
          <title>Multiple Dose VP 20629 300 mg</title>
          <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
        </group>
        <group group_id="P8">
          <title>Multiple Dose VP 20629 600 mg</title>
          <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
        </group>
        <group group_id="P9">
          <title>Multiple Dose VP 20629 900 mg</title>
          <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Single Dose Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Multiple Dose Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="6">Eligible participants who completed single dose treatment were randomized to multiple dose groups.</participants>
                <participants group_id="P7" count="6">Eligible participants who completed single dose treatment were randomized to multiple dose groups.</participants>
                <participants group_id="P8" count="6">Eligible participants who completed single dose treatment were randomized to multiple dose groups.</participants>
                <participants group_id="P9" count="6">Eligible participants who completed single dose treatment were randomized to multiple dose groups.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent-to-treat (ITT) set consisted of all participants who were randomly assigned to an investigational product treatment group. The baseline data for 14 participants who were randomised directly to multiple dose groups, was not summarised and not reported.</population>
      <group_list>
        <group group_id="B1">
          <title>Single Dose Placebo</title>
          <description>Participants received placebo matching to single dose of VP 20629 capsules orally under fasting condition on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Single Dose VP 20629 150 mg</title>
          <description>Participants received single dose of VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Single Dose VP 20629 450 mg</title>
          <description>Participants received single dose of VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Single Dose VP 20629 900 mg</title>
          <description>Participants received single dose of VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Single Dose VP 20629 1200 mg</title>
          <description>Participants received single dose of VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" spread="7.04"/>
                    <measurement group_id="B2" value="22.7" spread="1.97"/>
                    <measurement group_id="B3" value="27.8" spread="4.45"/>
                    <measurement group_id="B4" value="28.0" spread="6.90"/>
                    <measurement group_id="B5" value="26.8" spread="8.86"/>
                    <measurement group_id="B6" value="26.0" spread="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs (TEAEs), defined as all AEs that start during study drug treatment (and up to 7 days after the last dose of the study drug) and were not seen at baseline, or were seen at baseline but increased in frequency and/or severity during study drug treatment (and up to 7 days after the last dose of study drug).</description>
        <time_frame>From Start of Study Treatment up to Day 19</time_frame>
        <population>The ITT-safety (ITT-S) set consisted of all participants who were randomly assigned to an investigational product treatment group and who received at least 1 partial or complete dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose Placebo</title>
            <description>Participants received placebo matching to single dose of VP 20629 capsules orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 150 mg</title>
            <description>Participants received single dose of VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose of VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose of VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose of VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Multiple Dose Placebo</title>
            <description>Participants received placebo matching to multiple doses of VP 20629 capsules orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O7">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O8">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O9">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs (TEAEs), defined as all AEs that start during study drug treatment (and up to 7 days after the last dose of the study drug) and were not seen at baseline, or were seen at baseline but increased in frequency and/or severity during study drug treatment (and up to 7 days after the last dose of study drug).</description>
          <population>The ITT-safety (ITT-S) set consisted of all participants who were randomly assigned to an investigational product treatment group and who received at least 1 partial or complete dose of investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TESAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Laboratory Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Treatment-emergent were events between first dose of study drug and 7 days after the last dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with Grade 3 or higher treatment-emergent adverse events for laboratory abnormalities were reported as clinically relevant laboratory changes.</description>
        <time_frame>From Start of Study Treatment up to Day 19</time_frame>
        <population>The ITT-S set consisted of all participants who were randomly assigned to an investigational product treatment group and who received at least 1 partial or complete dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose Placebo</title>
            <description>Participants received placebo matching to single dose of VP 20629 capsules orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 150 mg</title>
            <description>Participants received single dose of VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose of VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose of VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose of VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Multiple Dose Placebo</title>
            <description>Participants received placebo matching to multiple doses of VP 20629 capsules orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O7">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O8">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O9">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Laboratory Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Treatment-emergent were events between first dose of study drug and 7 days after the last dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with Grade 3 or higher treatment-emergent adverse events for laboratory abnormalities were reported as clinically relevant laboratory changes.</description>
          <population>The ITT-S set consisted of all participants who were randomly assigned to an investigational product treatment group and who received at least 1 partial or complete dose of investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood Glucose Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophil Count Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>Vital sign assessments included systolic blood pressure, diastolic blood pressure, heart rate, and temperature. Vital signs abnormalities reported as TEAEs were reported.</description>
        <time_frame>From Start of Study Treatment up to Day 19</time_frame>
        <population>The ITT-S set consisted of all participants who were randomly assigned to an investigational product treatment group and who received at least 1 partial or complete dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose Placebo</title>
            <description>Participants received placebo matching to single dose of VP 20629 capsules orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 150 mg</title>
            <description>Participants received single dose of VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Multiple Dose Placebo</title>
            <description>Participants received placebo matching to multiple doses of VP 20629 capsules orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O7">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O8">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O9">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs Abnormalities Recorded as Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>Vital sign assessments included systolic blood pressure, diastolic blood pressure, heart rate, and temperature. Vital signs abnormalities reported as TEAEs were reported.</description>
          <population>The ITT-S set consisted of all participants who were randomly assigned to an investigational product treatment group and who received at least 1 partial or complete dose of investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Relevant Electrocardiogram (ECG) Abnormalities Recorded as Adverse Events (AEs)</title>
        <description>ECG included PR interval, QRS interval, QTcB interval, QTcF interval were considered as clinically significant ECG abnormalities.</description>
        <time_frame>From Start of Study Treatment up to Day 19</time_frame>
        <population>The ITT-S set consisted of all participants who were randomly assigned to an investigational product treatment group and who received at least 1 partial or complete dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose Placebo</title>
            <description>Participants received placebo matching to single dose of VP 20629 capsules orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 150 mg</title>
            <description>Participants received single dose VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Multiple Dose Placebo</title>
            <description>Participants received placebo matching to multiple doses of VP 20629 capsules orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O7">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O8">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O9">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Electrocardiogram (ECG) Abnormalities Recorded as Adverse Events (AEs)</title>
          <description>ECG included PR interval, QRS interval, QTcB interval, QTcF interval were considered as clinically significant ECG abnormalities.</description>
          <population>The ITT-S set consisted of all participants who were randomly assigned to an investigational product treatment group and who received at least 1 partial or complete dose of investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentration (Cmax) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
        <description>The Cmax is the maximum observed plasma concentration of single dose of VP 20629 and VP 20631.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose Placebo</title>
            <description>Participants received placebo matching to single dose of VP 20629 capsules orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 150 mg</title>
            <description>Participants received single dose VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
          <description>The Cmax is the maximum observed plasma concentration of single dose of VP 20629 and VP 20631.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629 (n=7,6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269" spread="92"/>
                    <measurement group_id="O2" value="29350" spread="6344"/>
                    <measurement group_id="O3" value="47350" spread="12742"/>
                    <measurement group_id="O4" value="76983" spread="7293"/>
                    <measurement group_id="O5" value="73717" spread="14848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631 (n=6,6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="2"/>
                    <measurement group_id="O2" value="1068" spread="353"/>
                    <measurement group_id="O3" value="3556" spread="2347"/>
                    <measurement group_id="O4" value="12515" spread="6056"/>
                    <measurement group_id="O5" value="15842" spread="12438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Observed Plasma Concentration (Tmax) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
        <description>The Tmax is the time to reach maximum observed plasma concentration of single dose of VP 20629 and VP 20631.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose Placebo</title>
            <description>Participants received placebo matching to single dose of VP 20629 capsules orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 150 mg</title>
            <description>Participants received single dose VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Plasma Concentration (Tmax) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
          <description>The Tmax is the time to reach maximum observed plasma concentration of single dose of VP 20629 and VP 20631.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629 (n=7,6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.94" spread="7.58"/>
                    <measurement group_id="O2" value="1.50" spread="0.45"/>
                    <measurement group_id="O3" value="1.92" spread="0.95"/>
                    <measurement group_id="O4" value="1.83" spread="0.61"/>
                    <measurement group_id="O5" value="3.01" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631(n=6,6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.71" spread="20.17"/>
                    <measurement group_id="O2" value="2.17" spread="0.41"/>
                    <measurement group_id="O3" value="2.83" spread="2.50"/>
                    <measurement group_id="O4" value="2.16" spread="0.60"/>
                    <measurement group_id="O5" value="3.35" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
        <description>The AUC is the area under the plasma concentration-time curve observed.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose VP 20629 150 mg</title>
            <description>Participants received single dose VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
          <description>The AUC is the area under the plasma concentration-time curve observed.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations.</population>
          <units>hour*nanogram per milliliter (h*ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152277" spread="27113"/>
                    <measurement group_id="O2" value="298443" spread="42925"/>
                    <measurement group_id="O3" value="463893" spread="44896"/>
                    <measurement group_id="O4" value="525976" spread="107856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5118" spread="1155"/>
                    <measurement group_id="O2" value="14208" spread="4117"/>
                    <measurement group_id="O3" value="33366" spread="9374"/>
                    <measurement group_id="O4" value="48322" spread="17989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC[0-8]) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
        <description>The AUC(0-8) is the area under the plasma concentration-time curve from time zero to 8 hours postdose.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, and 8 hours Postdose on Day 1</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose Placebo</title>
            <description>Participants received placebo matching to single dose of VP 20629 capsules orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 150mg</title>
            <description>Participants received single dose VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC[0-8]) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
          <description>The AUC(0-8) is the area under the plasma concentration-time curve from time zero to 8 hours postdose.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629 (n=7,6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1708" spread="693"/>
                    <measurement group_id="O2" value="95673" spread="10720"/>
                    <measurement group_id="O3" value="183398" spread="10155"/>
                    <measurement group_id="O4" value="302823" spread="31529"/>
                    <measurement group_id="O5" value="325019" spread="45937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631 (n=5,6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="27"/>
                    <measurement group_id="O2" value="3201" spread="802"/>
                    <measurement group_id="O3" value="9934" spread="4155"/>
                    <measurement group_id="O4" value="27426" spread="8969"/>
                    <measurement group_id="O5" value="37258" spread="19280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve to the Last Measurable Plasma Concentration (AUCt) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
        <description>The AUCt is the measure of the plasma drug concentration from time zero to time t.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose Placebo</title>
            <description>Participants received placebo matching to single dose of VP 20629 capsules orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 150 mg</title>
            <description>Participants received single dose VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve to the Last Measurable Plasma Concentration (AUCt) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
          <description>The AUCt is the measure of the plasma drug concentration from time zero to time t.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629 (n=7,6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9903" spread="4192"/>
                    <measurement group_id="O2" value="147287" spread="25078"/>
                    <measurement group_id="O3" value="294510" spread="41445"/>
                    <measurement group_id="O4" value="457563" spread="46848"/>
                    <measurement group_id="O5" value="519996" spread="106355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631 (n=6,6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164" spread="149"/>
                    <measurement group_id="O2" value="4876" spread="1201"/>
                    <measurement group_id="O3" value="14070" spread="4110"/>
                    <measurement group_id="O4" value="33121" spread="9322"/>
                    <measurement group_id="O5" value="48114" spread="17934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Plasma Half-Life (t1/2) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
        <description>The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose VP 20629 150 mg</title>
            <description>Participants received single dose VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Plasma Half-Life (t1/2) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
          <description>The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.98" lower_limit="8.46" upper_limit="13.56"/>
                    <measurement group_id="O2" value="7.87" lower_limit="7.62" upper_limit="8.46"/>
                    <measurement group_id="O3" value="7.43" lower_limit="4.40" upper_limit="9.44"/>
                    <measurement group_id="O4" value="7.85" lower_limit="6.62" upper_limit="8.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.19" lower_limit="9.14" upper_limit="15.09"/>
                    <measurement group_id="O2" value="7.85" lower_limit="7.13" upper_limit="8.22"/>
                    <measurement group_id="O3" value="7.72" lower_limit="4.52" upper_limit="9.46"/>
                    <measurement group_id="O4" value="6.95" lower_limit="6.29" upper_limit="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution (Vz/F) of VP 20629 for Single Dose Groups</title>
        <description>The Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose VP 20629 150 mg</title>
            <description>Participants received single dose VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vz/F) of VP 20629 for Single Dose Groups</title>
          <description>The Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="3.4"/>
                    <measurement group_id="O2" value="17.6" spread="2.9"/>
                    <measurement group_id="O3" value="20.8" spread="6.1"/>
                    <measurement group_id="O4" value="26.9" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Drug Clearance (CL/F) of VP 20629 for Single Dose Groups</title>
        <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose VP 20629 150 mg</title>
            <description>Participants received single dose VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Drug Clearance (CL/F) of VP 20629 for Single Dose Groups</title>
          <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations.</population>
          <units>liter per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.010" spread="0.171"/>
                    <measurement group_id="O2" value="1.533" spread="0.209"/>
                    <measurement group_id="O3" value="1.956" spread="0.196"/>
                    <measurement group_id="O4" value="2.357" spread="0.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Rate Constant (Lambda[z]) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
        <description>Lambda(z) is first-order elimination rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose VP 20629 150 mg</title>
            <description>Participants received single dose VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Rate Constant (Lambda[z]) of VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
          <description>Lambda(z) is first-order elimination rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations.</population>
          <units>per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0688" spread="0.0111"/>
                    <measurement group_id="O2" value="0.0874" spread="0.0033"/>
                    <measurement group_id="O3" value="0.1007" spread="0.0312"/>
                    <measurement group_id="O4" value="0.0892" spread="0.0105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0615" spread="0.0114"/>
                    <measurement group_id="O2" value="0.0889" spread="0.0046"/>
                    <measurement group_id="O3" value="0.0958" spread="0.0295"/>
                    <measurement group_id="O4" value="0.0972" spread="0.0124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Amount Excreted Into the Urine (Ae) for Unchanged VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
        <description>The Ae is the amount of drug excreted in urine. It is calculated by multiplying the urinary volume with the urinary drug concentration.</description>
        <time_frame>0-4, 4-8, 8-16, 16-24, 24-36 and 36-48 hours postdose on Day 1</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose VP 20629 150 mg</title>
            <description>Participants received single dose VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Amount Excreted Into the Urine (Ae) for Unchanged VP 20629 and Its Metabolite (VP 20631) for Single Dose Groups</title>
          <description>The Ae is the amount of drug excreted in urine. It is calculated by multiplying the urinary volume with the urinary drug concentration.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
          <units>microgram (mcg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" spread="17.2"/>
                    <measurement group_id="O2" value="79.4" spread="13.3"/>
                    <measurement group_id="O3" value="368.6" spread="196.3"/>
                    <measurement group_id="O4" value="518.1" spread="105.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131644.9" spread="19834.5"/>
                    <measurement group_id="O2" value="529022.1" spread="92223.8"/>
                    <measurement group_id="O3" value="953370.1" spread="116994.6"/>
                    <measurement group_id="O4" value="1263419.7" spread="190242.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Drug Excreted in Urine (Ae%) of VP 20629 for Single Dose Groups</title>
        <description>The Ae% is the percentage of drug dose excreted into the urine calculated as (Ae divided by dose)∗100.</description>
        <time_frame>-4, 4-8, 8-16, 16-24, 24-36 and 36-48 hours postdose on Day 1</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose VP 20629 150 mg</title>
            <description>Participants received single dose VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Drug Excreted in Urine (Ae%) of VP 20629 for Single Dose Groups</title>
          <description>The Ae% is the percentage of drug dose excreted into the urine calculated as (Ae divided by dose)∗100.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
          <units>percentage of dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0367" spread="0.0115"/>
                    <measurement group_id="O2" value="0.0176" spread="0.0030"/>
                    <measurement group_id="O3" value="0.0410" spread="0.0218"/>
                    <measurement group_id="O4" value="0.0432" spread="0.0088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance (CLR) of VP 20629 for Single Dose Groups</title>
        <description>The CLR is the renal clearance of the drug, calculated as Ae/AUC(0-infinity) on Day 1 or Ae(0-24)/AUC(0-24) on Day 1.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8,10, 12, 24 and 48 hours Postdose on Day 1</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose VP 20629 150 mg</title>
            <description>Participants received single dose VP 20629 capsules of 150 milligram (mg) orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose VP 20629 450 mg</title>
            <description>Participants received single dose VP 20629 capsules of 450 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose VP 20629 900 mg</title>
            <description>Participants received single dose VP 20629 capsules of 900 mg orally under fasting condition on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Single Dose VP 20629 1200 mg</title>
            <description>Participants received single dose VP 20629 capsules of 1200 mg orally under fasting condition on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CLR) of VP 20629 for Single Dose Groups</title>
          <description>The CLR is the renal clearance of the drug, calculated as Ae/AUC(0-infinity) on Day 1 or Ae(0-24)/AUC(0-24) on Day 1.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
          <units>liter per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0003" spread="0.0001"/>
                    <measurement group_id="O2" value="0.0003" spread="0.0001"/>
                    <measurement group_id="O3" value="0.0008" spread="0.0005"/>
                    <measurement group_id="O4" value="0.0010" spread="0.0002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentration (Cmax) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
        <description>The Cmax is the maximum observed plasma concentration of Multiple Dose of VP 20629 and VP 20631.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 24 and 72 hours Postdose on Day 1</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose Placebo</title>
            <description>Participants received placebo matching to multiple doses of VP 20629 capsules orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O4">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
          <description>The Cmax is the maximum observed plasma concentration of Multiple Dose of VP 20629 and VP 20631.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629 (n=6,6,6,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172" spread="82"/>
                    <measurement group_id="O2" value="21667" spread="2890"/>
                    <measurement group_id="O3" value="30000" spread="5592"/>
                    <measurement group_id="O4" value="40440" spread="8878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631 (n=1,6,6,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6">Standard deviation was not evaluable as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="556" spread="88"/>
                    <measurement group_id="O3" value="1270" spread="446"/>
                    <measurement group_id="O4" value="2094" spread="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentration at Steady State (Cmax,ss) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
        <description>The Cmax,ss is the maximum observed plasma concentration at steady state.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose Placebo</title>
            <description>Participants received placebo matching to multiple doses of VP 20629 capsules orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O4">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration at Steady State (Cmax,ss) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
          <description>The Cmax,ss is the maximum observed plasma concentration at steady state.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629 (n=6,5,6,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212" spread="54"/>
                    <measurement group_id="O2" value="25060" spread="10656"/>
                    <measurement group_id="O3" value="32583" spread="6941"/>
                    <measurement group_id="O4" value="45000" spread="3431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631 (n=4,5,6,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="3"/>
                    <measurement group_id="O2" value="754" spread="194"/>
                    <measurement group_id="O3" value="1638" spread="252"/>
                    <measurement group_id="O4" value="3156" spread="1305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Observed Plasma Concentration (Tmax) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
        <description>The Tmax is the time to reach maximum observed plasma concentration of multiple dose of VP 20629 and VP 20631.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 24 and 72 hours Postdose on Day 1</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose Placebo</title>
            <description>Participants received placebo matching to multiple doses of VP 20629 capsules orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O4">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Plasma Concentration (Tmax) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
          <description>The Tmax is the time to reach maximum observed plasma concentration of multiple dose of VP 20629 and VP 20631.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629 (n=6,6,6,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" spread="1.72"/>
                    <measurement group_id="O2" value="1.09" spread="0.38"/>
                    <measurement group_id="O3" value="1.42" spread="0.38"/>
                    <measurement group_id="O4" value="1.63" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631 (n=1,6,6,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58">Standard deviation was not evaluable as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="1.42" spread="0.49"/>
                    <measurement group_id="O3" value="1.59" spread="0.38"/>
                    <measurement group_id="O4" value="2.02" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Observed Plasma Concentration at Steady State (Tmax,ss) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
        <description>The Tmax,ss is the time to reach maximum observed plasma concentration at steady state of multiple dose of VP 20629 and VP 20631.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose Placebo</title>
            <description>Participants received placebo matching to multiple doses of VP 20629 capsules orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O4">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Plasma Concentration at Steady State (Tmax,ss) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
          <description>The Tmax,ss is the time to reach maximum observed plasma concentration at steady state of multiple dose of VP 20629 and VP 20631.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629 (n=6,5,6,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.65" spread="3.96"/>
                    <measurement group_id="O2" value="0.97" spread="0.04"/>
                    <measurement group_id="O3" value="2.00" spread="0.32"/>
                    <measurement group_id="O4" value="1.80" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631 (n=4,5,6,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.71"/>
                    <measurement group_id="O2" value="1.67" spread="0.42"/>
                    <measurement group_id="O3" value="2.26" spread="0.53"/>
                    <measurement group_id="O4" value="1.90" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
        <description>The AUC is the area under the plasma concentration-time curve observed.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
          <description>The AUC is the area under the plasma concentration-time curve observed.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
          <units>h*ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184407" spread="108180"/>
                    <measurement group_id="O2" value="217115" spread="58417"/>
                    <measurement group_id="O3" value="332140" spread="73876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5156" spread="1869"/>
                    <measurement group_id="O2" value="9299" spread="2402"/>
                    <measurement group_id="O3" value="14807" spread="2206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve at Steady State (AUCss) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
        <description>The AUCss is the area under the plasma concentration time curve observed during a dosing at steady state.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, and 8 hours Postdose on Day 8</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve at Steady State (AUCss) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
          <description>The AUCss is the area under the plasma concentration time curve observed during a dosing at steady state.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
          <units>h*ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99794" spread="44105"/>
                    <measurement group_id="O2" value="138567" spread="37102"/>
                    <measurement group_id="O3" value="196587" spread="18647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2848" spread="677"/>
                    <measurement group_id="O2" value="6006" spread="1215"/>
                    <measurement group_id="O3" value="9732" spread="1932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC[0-8]) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
        <description>The AUC(0-8) is the area under the plasma concentration-time curve from time zero to 8 hours postdose.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6 and 8 hours Postdose on Day 1</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;n&quot; is number of participants analyzed for this outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose Placebo</title>
            <description>Participants received placebo matching to multiple doses of VP 20629 capsules orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O4">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC[0-8]) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
          <description>The AUC(0-8) is the area under the plasma concentration-time curve from time zero to 8 hours postdose.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;n&quot; is number of participants analyzed for this outcome measure at given time points.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629 (n=6,6,6,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1080" spread="451"/>
                    <measurement group_id="O2" value="72054" spread="21395"/>
                    <measurement group_id="O3" value="113510" spread="26091"/>
                    <measurement group_id="O4" value="144059" spread="10302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631 (n=1,6,6,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20">Standard deviation was not evaluable as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="1926" spread="315"/>
                    <measurement group_id="O3" value="4130" spread="1137"/>
                    <measurement group_id="O4" value="5740" spread="1076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUCt) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
        <description>The AUCtau is the measure of the plasma drug concentration from time zero to time t.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose Placebo</title>
            <description>Participants received placebo matching to multiple doses of VP 20629 capsules orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O4">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUCt) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
          <description>The AUCtau is the measure of the plasma drug concentration from time zero to time t.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; (Number of participants analyzed) and &quot;n&quot; are number of participants analyzed for this outcome measure and for the specified compound, respectively.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629 (n=6,5,6,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6769" spread="1480"/>
                    <measurement group_id="O2" value="177487" spread="102429"/>
                    <measurement group_id="O3" value="212568" spread="57087"/>
                    <measurement group_id="O4" value="325464" spread="72038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631 (n=4,5,6,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" spread="124"/>
                    <measurement group_id="O2" value="4992" spread="1790"/>
                    <measurement group_id="O3" value="9103" spread="2358"/>
                    <measurement group_id="O4" value="14570" spread="2177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Plasma Half-Life (t1/2) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
        <description>The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Plasma Half-Life (t1/2) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
          <description>The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.95" spread="1.09"/>
                    <measurement group_id="O2" value="9.07" spread="1.21"/>
                    <measurement group_id="O3" value="9.05" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.01" spread="0.44"/>
                    <measurement group_id="O2" value="9.68" spread="1.45"/>
                    <measurement group_id="O3" value="9.11" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution (Vz/F) of VP 20629 for Multiple Dose Groups</title>
        <description>The Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vz/F) of VP 20629 for Multiple Dose Groups</title>
          <description>The Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
          <units>liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.05" spread="5.28"/>
                    <measurement group_id="O2" value="19.77" spread="4.62"/>
                    <measurement group_id="O3" value="20.03" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Drug Clearance at Steady State (CLss/F) of VP 20629 for Multiple Dose Groups</title>
        <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Drug Clearance at Steady State (CLss/F) of VP 20629 for Multiple Dose Groups</title>
          <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
          <units>liter per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.133" spread="0.388"/>
                    <measurement group_id="O2" value="1.524" spread="0.364"/>
                    <measurement group_id="O3" value="1.537" spread="0.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Rate Constant (Lambda[z]) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
        <description>Lambda(z) is first-order elimination rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Rate Constant (Lambda[z]) of VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
          <description>Lambda(z) is first-order elimination rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
          <units>per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0703" spread="0.0076"/>
                    <measurement group_id="O2" value="0.0775" spread="0.0094"/>
                    <measurement group_id="O3" value="0.0777" spread="0.0111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0693" spread="0.0031"/>
                    <measurement group_id="O2" value="0.0729" spread="0.0107"/>
                    <measurement group_id="O3" value="0.0768" spread="0.0085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Amount Excreted Into the Urine at Steady State (Ae,ss) of Unchanged VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
        <description>The Ae,ss is the amount of drug excreted in urine. It is calculated by multiplying the urinary volume with the urinary drug concentration.</description>
        <time_frame>0-4, 4-8, 8-16, 16-24, 24-36, and 36-48 hours postdose on Day 8</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Amount Excreted Into the Urine at Steady State (Ae,ss) of Unchanged VP 20629 and Its Metabolite (VP 20631) for Multiple Dose Groups</title>
          <description>The Ae,ss is the amount of drug excreted in urine. It is calculated by multiplying the urinary volume with the urinary drug concentration.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
          <units>microgram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VP 20629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" spread="48.1"/>
                    <measurement group_id="O2" value="111.4" spread="27.5"/>
                    <measurement group_id="O3" value="244.3" spread="226.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VP 20631</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110042" spread="10852"/>
                    <measurement group_id="O2" value="254540" spread="52440"/>
                    <measurement group_id="O3" value="283873" spread="78764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Drug Excreted in Urine at Steady-State (Ae%,ss) of VP 20629 for Multiple Dose Groups</title>
        <description>The Ae%,ss is the percentage of drug dose excreted into the urine calculated as (Ae divided by dose)∗100.</description>
        <time_frame>0-4, 4-8, 8-16, 16-24, 24-36, and 36-48 hours postdose on Day 8</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Drug Excreted in Urine at Steady-State (Ae%,ss) of VP 20629 for Multiple Dose Groups</title>
          <description>The Ae%,ss is the percentage of drug dose excreted into the urine calculated as (Ae divided by dose)∗100.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
          <units>percentage of dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0568" spread="0.0481"/>
                    <measurement group_id="O2" value="0.0557" spread="0.0138"/>
                    <measurement group_id="O3" value="0.0814" spread="0.0755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance at Steady State (CLR,ss) of VP 20629 for Multiple Dose Groups</title>
        <description>The CLR,ss is the renal clearance of the drug, calculated as Ae/AUC(0-infinity) on Day 8.</description>
        <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 48 hours Postdose on Day 8</time_frame>
        <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose VP 20629 300 mg</title>
            <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose VP 20629 600 mg</title>
            <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>Multiple Dose VP 20629 900 mg</title>
            <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance at Steady State (CLR,ss) of VP 20629 for Multiple Dose Groups</title>
          <description>The CLR,ss is the renal clearance of the drug, calculated as Ae/AUC(0-infinity) on Day 8.</description>
          <population>The pharmacokinetic set consisted of participants who had quantifiable VP 20629 plasma concentrations. Here, &quot;N&quot; is number of participants analyzed for this outcome measure.</population>
          <units>liter per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0005" spread="0.0002"/>
                    <measurement group_id="O2" value="0.0009" spread="0.0004"/>
                    <measurement group_id="O3" value="0.0013" spread="0.0013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of the study drug administration upto 30 days after the last dose of study drug administration.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single Dose Placebo</title>
          <description>Participants received placebo matching to single dose of VP 20629 capsules orally under fasting conditions on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Single Dose VP 20629 150mg</title>
          <description>Participants received single dose VP 20629 capsules of 150 milligram (mg) orally under fasting conditions on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Single Dose VP 20629 450mg</title>
          <description>Participants received single dose VP 20629 capsules of 450 mg orally under fasting conditions on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Single Dose VP 20629 900mg</title>
          <description>Participants received single dose VP 20629 capsules of 900 mg orally under fasting conditions on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Single Dose VP 20629 1200mg</title>
          <description>Participants received single dose VP 20629 capsules of 1200 mg orally under fasting conditions on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Multiple Dose Placebo</title>
          <description>Participants received placebo matching to multiple doses of VP 20629 capsules orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
        </group>
        <group group_id="E7">
          <title>Multiple Dose VP 20629 300mg</title>
          <description>Participants received VP 20629 capsules 300 mg total daily dose in 3 divided doses (100 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
        </group>
        <group group_id="E8">
          <title>Multiple Dose VP 20629 600mg</title>
          <description>Participants received VP 20629 capsules 600 mg total daily dose in 3 divided doses (200 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
        </group>
        <group group_id="E9">
          <title>Multiple Dose VP 20629 900mg</title>
          <description>Participants received VP 20629 capsules 900 mg total daily dose in 3 divided doses (300 mg every 8 hours) orally daily from Day 1 to Day 8 morning under fasting conditions.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cardiac discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Electrocardiogram qt prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution may publish results generated from the site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire</organization>
      <phone>1 866-842-5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

